PL373649A1 - Inhibitory kinazy - Google Patents

Inhibitory kinazy

Info

Publication number: PL373649A1
Authority: PL; Poland
Prior art keywords: kinase inhibitors; kinase; inhibitors
Prior art date: 2002-03-21

Application number

PL03373649A

Other languages

English (en)

Inventor

Gavin C. Hirst

Lee D. Arnold

Andrew Burchat

Neil Wishart

David Calderwood

Carol K. Wada

Michael R. Michaelides

Zhiqin Ji

Melanie Muckey

Original Assignee

Abbott Laboratories

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-03-21

Filing date

2003-03-21

Publication date

2005-09-05

2003-03-21 Application filed by Abbott Laboratories filed Critical Abbott Laboratories

2005-09-05 Publication of PL373649A1 publication Critical patent/PL373649A1/pl

Links

229940043355 kinase inhibitor Drugs 0.000 title 1
239000003757 phosphotransferase inhibitor Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Diabetes (AREA)
Virology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Hematology (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pulmonology (AREA)
Ophthalmology & Optometry (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Reproductive Health (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Gynecology & Obstetrics (AREA)
AIDS & HIV (AREA)
Vascular Medicine (AREA)
Biotechnology (AREA)
Transplantation (AREA)
Obesity (AREA)
Pregnancy & Childbirth (AREA)
Pain & Pain Management (AREA)

PL03373649A 2002-03-21 2003-03-21 Inhibitory kinazy PL373649A1 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US10/103,098 US20030199525A1 (en)	2002-03-21	2002-03-21	Kinase inhibitors

Publications (1)

Publication Number	Publication Date
PL373649A1 true PL373649A1 (pl)	2005-09-05

Family

ID=28452362

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL03373649A PL373649A1 (pl)	2002-03-21	2003-03-21	Inhibitory kinazy

Country Status (11)

Country	Link
US (1)	US20030199525A1 (pl)
EP (1)	EP1496910A4 (pl)
JP (1)	JP4707167B2 (pl)
AR (1)	AR039112A1 (pl)
AU (1)	AU2003222055A1 (pl)
CA (1)	CA2477651A1 (pl)
MX (1)	MXPA04009140A (pl)
PL (1)	PL373649A1 (pl)
TW (1)	TW200304818A (pl)
UY (1)	UY27729A1 (pl)
WO (1)	WO2003080064A1 (pl)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2004536579A (ja) *	2001-04-13	2004-12-09	ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド	血管内皮増殖因子２
AU2002252631A1 (en) *	2001-04-13	2002-10-28	Human Genome Sciences, Inc.	Vascular endothelial growth factor 2
US20050232921A1 (en) *	2001-04-13	2005-10-20	Rosen Craig A	Vascular endothelial growth factor 2
US20030225098A1 (en) *	2002-03-21	2003-12-04	Hirst Gavin C.	Kinase inhibitors
CA2546192C (en)	2003-11-17	2010-04-06	Pfizer Products Inc.	Pyrrolopyrimidine compounds useful in treatment of cancer
EP1689753A4 (en) *	2003-12-04	2010-07-07	Glaxosmithkline Llc	NEW CHEMICAL COMPOUNDS
ATE402705T1 (de) *	2003-12-24	2008-08-15	Astrazeneca Ab	Pyrimidine mit tie2 (tek) aktivität
JP2007520559A (ja) *	2004-02-03	2007-07-26	アボット・ラボラトリーズ	治療薬としてのアミノベンゾオキサゾール類
TW200530236A (en)	2004-02-23	2005-09-16	Chugai Pharmaceutical Co Ltd	Heteroaryl phenylurea
EP2168968B1 (en)	2004-04-02	2017-08-23	OSI Pharmaceuticals, LLC	6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
WO2005120513A1 (en) *	2004-06-09	2005-12-22	Oncalis Ag	Protein kinase inhibitors
MXPA06015223A (es) *	2004-06-29	2007-11-09	Amgen Inc	Furanopirimidinas.
US7674907B2 (en) *	2004-07-23	2010-03-09	Amgen Inc.	Furanopyridine derivatives and methods of use
ES2438017T3 (es)	2004-07-30	2014-01-15	Methylgene Inc.	Inhibidores de la señalización del receptor del VEGF y del receptor del HGF
JP2008508358A (ja) *	2004-08-02	2008-03-21	オーエスアイ・ファーマスーティカルズ・インコーポレーテッド	アリール−アミノ置換ピロロピリミジンマルチキナーゼ阻害化合物
ES2368930T3 (es)	2004-09-06	2011-11-23	Bayer Pharma Aktiengesellschaft	Pirazolopirimidinas como inhibidores de proteína cinasa b (akt).
ATE554087T1 (de)	2004-10-29	2012-05-15	Abbott Lab	Neue kinaseinhibitoren
ATE525073T1 (de) *	2005-01-28	2011-10-15	Novartis Ag	Verwendung von pyrimidylaminobenzamiden zur behandlung von durch modulation einer tie-2 kinase-aktivität verursachten krankheiten
TW200640443A (en) *	2005-02-23	2006-12-01	Alcon Inc	Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
DE102005017259A1 (de) *	2005-04-14	2006-10-19	Merck Patent Gmbh	Purinderivate
AU2006313456B2 (en)	2005-05-20	2011-06-23	Methylgene Inc.	Inhibitors of VEGF receptor and HGF receptor signaling
KR100670171B1 (ko) *	2005-06-25	2007-01-17	한국과학기술연구원	신규 퓨로[２,３-ｄ]피리미딘계 Ａｋｔ1 키나아제 저해제,그 제조 중간체 및 이들의 제조 방법
WO2007064931A2 (en) *	2005-12-02	2007-06-07	Bayer Healthcare Llc	Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
PE20070855A1 (es)	2005-12-02	2007-10-14	Bayer Pharmaceuticals Corp	Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
JP5237108B2 (ja) *	2005-12-08	2013-07-17	アボット・ラボラトリーズ	タンパク質キナーゼ阻害薬としての９員ヘテロ二環式化合物
US8575164B2 (en)	2005-12-19	2013-11-05	OSI Pharmaceuticals, LLC	Combination cancer therapy
EP1962803A1 (en) *	2005-12-23	2008-09-03	Alcon, Inc.	PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
DE102007027799A1 (de) *	2007-06-16	2008-12-18	Bayer Healthcare Ag	Substituierte Furopyrimidine und ihre Verwendung
DE102007054786A1 (de)	2007-11-16	2009-05-20	Bayer Healthcare Ag	Trisubstituierte Furopyrimidine und ihre Verwendung
EA201001030A1 (ru)	2007-12-19	2011-02-28	Амген Инк.	Конденсированные соединения пиридина, пиримидина и триазина в качестве ингибиторов клеточного цикла
NZ588355A (en)	2008-03-05	2012-03-30	Methylgene Inc	Inhibitors of protein tyrosine kinase activity
US8389533B2 (en)	2008-04-07	2013-03-05	Amgen Inc.	Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
ES2396613T3 (es)	2008-05-19	2013-02-22	OSI Pharmaceuticals, LLC	Imidazopirazinas e imidazotriazinas sustituidas
US8946239B2 (en) *	2008-07-10	2015-02-03	Duquesne University Of The Holy Spirit	Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof
WO2010033941A1 (en)	2008-09-22	2010-03-25	Array Biopharma Inc.	Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors
MY169791A (en)	2008-10-22	2019-05-15	Array Biopharma Inc	Substituted pyrazolo [1,5-a] pyrimidine compounds as trk kinase inhibitors
US8513415B2 (en)	2009-04-20	2013-08-20	OSI Pharmaceuticals, LLC	Preparation of C-pyrazine-methylamines
AR077468A1 (es)	2009-07-09	2011-08-31	Array Biopharma Inc	Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
WO2011018894A1 (en) *	2009-08-10	2011-02-17	Raqualia Pharma Inc.	Pyrrolopyrimidine derivatives as potassium channel modulators
US20120301463A1 (en)	2009-09-30	2012-11-29	President And Fellows Of Harvard College	Methods for Modulation of Autophagy Through the Modulation of Autophagy-Enhancing Gene Products
WO2011044019A1 (en) *	2009-10-05	2011-04-14	Bristol-Myers Squibb Company	(R)-1-(4-(4-FLUORO-2-METHYL-1H-INDOL-5-YLOXY)-5-METHYLPYRROLO[2,1-f][1,2,4]TRIAZIN-6-YLOXY)PROPAN-2-OL METABOLITES
ME03376B (me)	2010-05-20	2020-01-20	Array Biopharma Inc	Makrociklička jedinjenja kао inhibiтori trk kinaze
RU2013120966A (ru)	2010-10-08	2014-11-20	Эббви Инк.	ФУРО[3,2-d]ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ
EP2937349B1 (en)	2011-03-23	2016-12-28	Amgen Inc.	Fused tricyclic dual inhibitors of cdk 4/6 and flt3
CA2846496C (en) *	2011-09-02	2020-07-14	The Regents Of The University Of California	Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
MX371331B (es)	2012-04-24	2020-01-27	Vertex Pharma	Inhibidores de la proteina cinasa dependiente de acido desoxirribonucleico(adn-pk).
CA2782774A1 (en) *	2012-07-06	2014-01-06	Pharmascience Inc.	Protein kinase inhibitors
MX2015011428A (es)	2013-03-06	2016-02-03	Genentech Inc	Metodos para tratar y prevenir la resistencia a los farmacos para el cancer.
ME03336B (me)	2013-03-12	2019-10-20	Vertex Pharma	Inhibitori dnk-pk
JP6408569B2 (ja)	2013-10-17	2018-10-17	バーテックスファーマシューティカルズインコーポレイテッドＶｅｒｔｅｘＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃｏｒｐｏｒａｔｅｄ	Ｄｎａ−ｐｋ阻害剤としての（ｓ）−ｎ−メチル−８−（１−（（２’−メチル−［４，５’−ビピリミジン］−６−イル）アミノ）プロパン−２−イル）キノリン−４−カルボキサミドおよびその重水素化誘導体の共結晶
CN103880861B (zh) *	2014-02-21	2016-02-03	温州医科大学	一种作用于FGF受体的4,6-二甲基-噁唑并[5,4-d]嘧啶-5,7（4H,6H）-二酮衍生物
CN107073121A (zh)	2014-06-13	2017-08-18	基因泰克公司	治疗及预防癌症药物抗性的方法
CN104311567B (zh) *	2014-11-11	2016-04-27	上海应用技术学院	一种制备4-氨基-3-(4-氨基苯)呋喃并[2,3-d]嘧啶的方法
CN113354649B (zh)	2014-11-16	2024-12-10	阵列生物制药公司	一种新的晶型
EP3368039A1 (en)	2015-10-26	2018-09-05	The Regents of The University of Colorado, A Body Corporate	Point mutations in trk inhibitor-resistant cancer and methods relating to the same
US10045991B2 (en)	2016-04-04	2018-08-14	Loxo Oncology, Inc.	Methods of treating pediatric cancers
FI3439662T3 (fi)	2016-04-04	2024-09-04	Loxo Oncology Inc	(s)-n-(5-((r)-2-(2,5-difluorifenyyli)pyrrolidin-1-yyli)pyratsolo[1,5-a]pyrimidin-3-yyli)-3-hydroksipyrrolidiini-1-karboksamidin nesteformulaatioita
EP3458456B1 (en)	2016-05-18	2020-11-25	Loxo Oncology Inc.	Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
EP3518931A4 (en)	2016-09-27	2020-05-13	Vertex Pharmaceuticals Incorporated	METHOD FOR TREATING CANCER WITH A COMBINATION OF DNA-DAMAGING SUBSTANCES AND DNA-PK INHIBITORS
JOP20190092A1 (ar)	2016-10-26	2019-04-25	Array Biopharma Inc	عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
JOP20190213A1 (ar)	2017-03-16	2019-09-16	Array Biopharma Inc	مركبات حلقية ضخمة كمثبطات لكيناز ros1
IL302807A (en)	2020-11-18	2023-07-01	Deciphera Pharmaceuticals Llc	Gcn2 and perk kinase inhibitors and methods of use thereof
CN113214274B (zh) *	2021-05-12	2022-03-11	广西中医药大学	八氢呋喃[2,3-b]吡啶-4,6-二醇及其制备方法和应用
PE20250609A1 (es)	2021-12-03	2025-02-26	Deciphera Pharmaceuticals Llc	Inhibidores de gcn2 y perk quinasa y metodos de uso de los mismos
GB202407386D0 (en) *	2024-05-24	2024-07-10	Apollo Ap45 Ltd	1H-pyrazolo(4,3-D)pyrimidine derivatives

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR205234A1 (es) *	1974-05-13	1976-04-12	Lilly Co Eli	Procedimiento p a r a preparar compuestos de 3-(5-nitroimidazol-2-il) pirazolo (3,4-d) pirimidina
US4966849A (en) *	1985-09-20	1990-10-30	President And Fellows Of Harvard College	CDNA and genes for human angiogenin (angiogenesis factor) and methods of expression
US5217999A (en) *	1987-12-24	1993-06-08	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Styryl compounds which inhibit EGF receptor protein tyrosine kinase
US5795977A (en) *	1989-09-15	1998-08-18	Metabasis Therapeutics, Inc.	Water soluble adenosine kinase inhibitors
US5763596A (en) *	1989-09-15	1998-06-09	Metabasis Therapeutics, Inc.	C-4' modified adenosine kinase inhibitors
US5726302A (en) *	1989-09-15	1998-03-10	Gensia Inc.	Water soluble adenosine kinase inhibitors
US5302606A (en) *	1990-04-16	1994-04-12	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
US5877178A (en) *	1991-04-08	1999-03-02	Duquesne University Of The Holy Ghost	Pyrimidine derivatives and methods of making and using these derivatives
US5330992A (en) *	1992-10-23	1994-07-19	Sterling Winthrop Inc.	1-cyclopropyl-4-pyridyl-quinolinones
AU4779897A (en) *	1996-10-02	1998-04-24	Novartis Ag	Fused pyrazole derivatives and processes for their preparation
TR199902301T2 (xx) *	1997-03-19	1999-12-21	Basf Aktiengesellschaft	Pirilo $2,3D]pirimidinler ve onlar�n kullan�m�.
US6921763B2 (en) *	1999-09-17	2005-07-26	Abbott Laboratories	Pyrazolopyrimidines as therapeutic agents
JP2003509428A (ja) *	1999-09-17	2003-03-11	アボツト・ゲー・エム・ベー・ハー・ウント・コンパニー・カーゲー	治療薬としてのピラゾロピリミジン
AU2000240570A1 (en) *	2000-03-29	2001-10-08	Knoll Gesellschaft Mit Beschraenkter Haftung	Pyrrolopyrimidines as tyrosine kinase inhibitors
MXPA03008560A (es) *	2001-03-22	2004-06-30	Abbot Gmbh & Co Kg	Pirazolopirimidinas como agentes terapeuticos.
AU2002333524A1 (en) *	2001-09-11	2003-03-24	Glaxosmithkline K.K.	Furo-and thienopyrimidine derivatives as angiogenesis inhibitors

2002
- 2002-03-21 US US10/103,098 patent/US20030199525A1/en not_active Abandoned
2003
- 2003-03-21 UY UY27729A patent/UY27729A1/es not_active Application Discontinuation
- 2003-03-21 WO PCT/US2003/008950 patent/WO2003080064A1/en not_active Ceased
- 2003-03-21 TW TW092106320A patent/TW200304818A/zh unknown
- 2003-03-21 JP JP2003577890A patent/JP4707167B2/ja not_active Expired - Fee Related
- 2003-03-21 AU AU2003222055A patent/AU2003222055A1/en not_active Abandoned
- 2003-03-21 PL PL03373649A patent/PL373649A1/pl not_active Application Discontinuation
- 2003-03-21 AR ARP030101009A patent/AR039112A1/es not_active Application Discontinuation
- 2003-03-21 CA CA002477651A patent/CA2477651A1/en not_active Abandoned
- 2003-03-21 EP EP03718039A patent/EP1496910A4/en not_active Withdrawn
- 2003-03-21 MX MXPA04009140A patent/MXPA04009140A/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
MXPA04009140A (es)	2004-11-26
EP1496910A4 (en)	2006-03-29
AR039112A1 (es)	2005-02-09
UY27729A1 (es)	2003-10-31
WO2003080064A1 (en)	2003-10-02
AU2003222055A1 (en)	2003-10-08
EP1496910A1 (en)	2005-01-19
US20030199525A1 (en)	2003-10-23
CA2477651A1 (en)	2003-10-02
JP2005530713A (ja)	2005-10-13
JP4707167B2 (ja)	2011-06-22
TW200304818A (en)	2003-10-16

Legal Events

Date	Code	Title	Description
2012-01-31	REFS	Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)

Publication	Publication Date	Title
PL373649A1 (pl)	2005-09-05	Inhibitory kinazy
SI1569907T1 (sl)	2016-06-30	Na nikotinamidu osnovani kinazni inhibitorji
AU2003271566A8 (en)	2004-03-03	Pyrrolopyrazines as kinase inhibitors
EP1558609A4 (en)	2008-05-28	KINASE INHIBITORS
EG25482A (en)	2012-01-15	Inhibitors
EP1543009A4 (en)	2007-08-08	Pyrrolotriazine KINASE INHIBITORS
AU2003249442A1 (en)	2004-02-16	Kinase inhibitors
IL165515A0 (en)	2006-01-15	Bisindolyl-maleimid derivatives as kinase inhibitors
AU2003299651A8 (en)	2004-06-30	Tyrosine kinase inhibitors
PL375352A1 (pl)	2005-11-28	Azaindolowe inhibitory kinaz
IL173381A0 (en)	2006-06-11	2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
SI2256108T1 (sl)	2016-05-31	Substituirani triazinski kinazni inhibitorji
AP2006003620A0 (en)	2006-06-30	Imidazopyrazine tyroshine kinase inhibitors
AP2048A (en)	2009-09-24	Diazepinoindole derivatives as kinase inhibitors
AU2003298942A8 (en)	2004-06-30	Tyrosine kinase inhibitors
AU2003282891A8 (en)	2004-04-23	Novel tyrosine kinases inhibitors
AU2003245555A1 (en)	2003-12-31	Sphingosine kinase inhibitors
IL172132A0 (en)	2006-04-10	Thienopyridone derivatives as kinase inhibitors
EP1581539A4 (en)	2007-09-19	NEW TYROSINE KINASE HEMMER
AU2003275282A8 (en)	2004-04-23	Novel tyrosine kinase inhibitors
AU2003254051A8 (en)	2004-02-09	Pyrazolopyrimidines as kinase inhibitors
EP1569907A4 (en)	2007-10-31	NICOTINAMIDE-BASED KINASE HEMMER
EP1532133A4 (en)	2006-11-15	NF-: B INHIBITORS
PL378116A1 (pl)	2006-03-06	Heterocykliczne inhibitory kinazy
AUPS251402A0 (en)	2002-06-13	Kinase inhibitors